LF
AXDX icon

Lee Financial’s Accelerate Diagnostics AXDX Stock Holding History

Lee Financial’s Portfolio AXDX Stock Details AXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-560
Closed -$125K – 481
2018
Q2 		$125K Hold
560
– – 0.03% 194
2018
Q1 		$128K Buy
+560
New +$147K 0.03% 187

Other funds holding AXDX

OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return
AAMU
Amundi Asset Management US Boston, Massachusetts $131B AUM 73.57% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $4.32B AUM 31.14% 1-Year Est. Return

Lee Financial's AXDX Position: Q3 2018 in Review

Lee Financial sold out of Accelerate Diagnostics (AXDX) in Q3 2018, closing a stake of 560 shares — an estimated $125K sold.

Lee Financial first reported a position in AXDX in Q1 2018 and held it in 2 quarters. The position peaked at $128K in Q1 2018. 118 funds tracked by Wall St. Rank hold AXDX as of Q3 2018.

  • Lee Financial reported no remaining Accelerate Diagnostics position as of Q3 2018 after selling out during the quarter.
  • Lee Financial sold 560 Accelerate Diagnostics shares in Q3 2018, an estimated $125K.
  • Lee Financial first reported a position in Accelerate Diagnostics in Q1 2018 and held it in 2 quarters.
  • Lee Financial's Accelerate Diagnostics position peaked at $128K in Q1 2018.
  • 118 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q3 2018.

Based on Lee Financial's 13F filing for Q3 2018, filed 7 Nov 2018.